Drug Discovery & DDS Weekly Report May 13, 2026

Reliability of AI Antibody Design Hinges on Training Data: AlphaFold Era Highlights Data Quality Challenge

FDA Streamlines Nonclinical Studies for Biologics and Conjugated Products, Accepting NAMs for ADCs to Reduce Non-Human Primate Use

Imperial College London’s DeCAF-Pearl AI Model Enables Practical Large-Scale Molecular Screening, Surpassing AlphaFold 3 Efficiency

UVA’s YuelDesign AI Framework Models Protein Flexibility for Improved Drug Design, Demonstrating Success on CDK2 Target

Latent Labs’ Generative AI Transforms Molecular Design, Producing Macrocyclic Peptides and Antibody Candidates in Weeks

ThinkBio.Ai Leads AI Drug Discovery Tools Market, Innovating Target Identification and Clinical Trial Planning

GLP-1 Market Heats Up with Oral Therapies and Triple Agonists for Obesity, Metabolic Health Opportunity Nears $150 Billion

Isomorphic Labs Advances AI-Designed Oncology and Immunology Therapeutics to Clinical Trials Leveraging AlphaFold 3